Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

SERCA 2a gene therapy - Celladon Corporation

Drug Profile

SERCA 2a gene therapy - Celladon Corporation

Alternative Names: AAV1/SERCA2a; Congestive heart failure gene therapy; MYDICAR; rAAV1-SERCA2a; SERCA2a gene therapy

Latest Information Update: 06 Jul 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Celladon; Targeted Genetics
  • Developer Celladon; Theragene Pharmaceuticals
  • Class Gene therapies; Heart failure therapies
  • Mechanism of Action Adenosine triphosphatase stimulants; Gene transference; Sarcoplasmic reticulum calcium-transporting ATPase modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Heart failure
  • Preclinical Pulmonary arterial hypertension; Renal failure
  • Discontinued Urinary incontinence

Most Recent Events

  • 29 Jun 2017 Theragene Pharmaceuticals acquires Mydicar® (rAAV1-SERCA2a) from Eiger BioPharmaceuticals
  • 29 Jun 2017 Phase-II clinical trials in Heart failure in France, Sweden, United Kingdom, Hungary, Poland, Israel, Netherlands, Germany, Denmark, Belgium, USA (Intracoronary)
  • 29 Jun 2017 Preclinical trials in Pulmonary arterial hypertension in USA (Inhalation)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top